Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Optical Biosensor Reduces Time for Sepsis Diagnosis

By LabMedica International staff writers
Posted on 12 Feb 2020
New point‐of‐care diagnostic devices are urgently needed for rapid and accurate diagnosis, particularly in the management of life‐threatening infections and sepsis, where immediate treatment is key.

A novel portable biosensor based on nanoparticle‐enhanced digital plasmonic imaging has been developed for rapid and sensitive detection of two sepsis‐related inflammatory biomarkers, procalcitonin (PCT) and C‐reactive protein (CRP) directly from blood serum.

Bioengineers from the Ecole Polytechnique Fédérale de Lausanne (Lausanne, Switzerland) and their colleagues drew on recent developments in nanotechnology and on light effects at a nanoscale to create a highly portable, easy-to-use device that can rapidly detect sepsis biomarkers in a patient's bloodstream, and their device takes just a few minutes to deliver a result, like a pregnancy test.

The device employs an optical metasurface, in this case a thin gold sheet containing arrays of billions of nanoholes. More...
The metasurface concentrates light around the nanoholes so as to allow for exceptionally precise biomarker detection. With this type of metasurface, the team can detect sepsis biomarkers in a blood sample with nothing more than a simple LED and a standard CMOS camera. The team began by adding a solution of special nanoparticles to the sample that are designed to capture the biomarkers and then distribute this mixture on the metasurface.

The generated images are used to rapidly determine whether disease biomarkers are present in a sample and, if so, in what concentration. They used the new device to measure the blood serum levels of two important sepsis relevant biomarkers, PCT and CRP. Doctors can use this information to accelerate the triage of sepsis patients, ultimately saving lives. The device was installed at the Vall d'Hebron University Hospital (Barcelona, Spain) and used in blind tests to examine patient samples from the hospital's sepsis bank.

The authors concluded that portable digital nanoparticle‐enhanced plasmonic imager that enables rapid detection of two inflammatory sepsis‐related biomarkers, PCT and CRP. The unique nanoplasmonic mechanism through imaging of single gold nanoparticles (Au‐NPs) binding on the gold nanohole arrays (Au‐NHAs) enables highly sensitive and rapid biomarker detection directly in blood serum. The compact nanoplasmonic reader, built of inexpensive components, weighs less than 1 kg. The study was published on January 23, 2020 in the journal Small.

Related Links:
Ecole Polytechnique Fédérale de Lausanne
Vall d'Hebron University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.